FDA CBER leadership transition aims to stabilize operations and review past regulatory decisions

Karim Mikhail has assumed leadership of the FDA's Center for Biologics Evaluation and Research (CBER) with a mandate to improve internal morale and re-evaluate controversial drug application rejections. The initiative signals a potential shift in regulatory posture following a period of internal instability, though the extent of policy reversals remains uncertain.